SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Angiology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Petruzzellis, V.
Right arrow Articles by Dugall, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Petruzzellis, V.
Right arrow Articles by Dugall, M.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Oxerutins (Venoruton®): Efficacy in Chronic Venous Insufficiency

A Double-Blind, Randomized, Controlled Study

Vincenzo Petruzzellis, MD

Dermatology Department, Di Venere-Giovanni XIII Hospital, Bari-Carbonara; and Irvine2 Vascular Laboratory, Department of Biomedical Sciences, Chieti University, Italy.

Teresa Troccoli, MD

Dermatology Department, Di Venere-Giovanni XIII Hospital, Bari-Carbonara; and Irvine2 Vascular Laboratory, Department of Biomedical Sciences, Chieti University, Italy.

Carlo Candiani, MD

Dermatology Department, Di Venere-Giovanni XIII Hospital, Bari-Carbonara; and Irvine2 Vascular Laboratory, Department of Biomedical Sciences, Chieti University, Italy.

Raffaella Guarisco, FHD

Dermatology Department, Di Venere-Giovanni XIII Hospital, Bari-Carbonara; and Irvine2 Vascular Laboratory, Department of Biomedical Sciences, Chieti University, Italy.

Mario Lospalluti, MD

Dermatology Department, Di Venere-Giovanni XIII Hospital, Bari-Carbonara; and Irvine2 Vascular Laboratory, Department of Biomedical Sciences, Chieti University, Italy.

Gianni Belcaro, MD, PhD

Dermatology Department, Di Venere-Giovanni XIII Hospital, Bari-Carbonara; and Irvine2 Vascular Laboratory, Department of Biomedical Sciences, Chieti University, Italy.

Mark Dugall, MD

Dermatology Department, Di Venere-Giovanni XIII Hospital, Bari-Carbonara; and Irvine2 Vascular Laboratory, Department of Biomedical Sciences, Chieti University, Italy.

The aim of this study was to confirm the clinical efficacy of oxerutins by evaluation of venous parietal tone and microvascular perfusion in a double-blind, randomized, placebo-controlled study. The study included 60 patients. Venous tone was evaluated by air-plethysmography (APG) in patients with venous insufficiency (CVI). Forty patients were treated with oxerutins and 20 with placebo for 4 weeks. The dose of the first 2 weeks was higher than that of the following 2 weeks. The age range was between 18 and 65 years. Randomized patients received treatment (oxerutins or placebo) according to the grade of CVI. Patients with grade I CVI received 2 g/day in the first 2 weeks of treatment and 1 g/day in the following weeks. Patients with grade II CVI received 3 g/day in the first 2 weeks and 2 g/day in the following 2 weeks. Visits were scheduled at baseline time (visit 1), at 2 weeks (visit 2) and at 4 weeks (visit 3). They were assessed with the following: (1) APG; (2) light reflection rheography (LRR); (3) capillaroscopy; (4) liquid crystals thermography. CVI signs/symptoms-heavy legs, edema, paresthesia, and cramps-were evaluated following a 4-point rating scale (0 = no symptom; 3 = severe symptoms). At visit 3 a final opinion on efficacy was provided by both patients and investigators, based on a 4-point scale (none, fairly good, good, excellent). The two groups were homogeneous for age, sex, and clinical distribution. The changes in venous capacity, were significant (p< 0.01) in the oxerutins group at visits 2 and 3; values in the placebo group remained unchanged. The changes in LRR were significant in the treatment group at visits 2 (p < 0.05) and 3 (p < 0.01); values in the placebo group remained unchanged. Changes in temperature were significant in the oxerutins group at visits 2 (p < 0.05) and 3 (p < 0.01 ); changes in the placebo group were not significant at the end of the study. Capillaroscopy showed an improvement in patients treated with oxerutins. The results of the analysis of signs/symptoms favored active treatment. The overall effects of oxerutins were significantly better than the effects of placebo. Considering both noninvasive tests and clinical evaluation, oxerutins is effective in controlling chronic venous hypertension, without side effect, and with good tolerability.

Angiology, Vol. 53, No. 3, 257-263 (2002)
DOI: 10.1177/000331970205300302


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement